ARCHER 1042: A PHASE 2 STUDY OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (POST-CHEMOTHERAPY OR SELECT FIRST LINE PATIENTS) TO EVALUATE PROPHYLACTIC INTERVENTION ON DERMATOLOGIC AND GASTROINTESTINAL ADVERSE EVENTS AND PATIENT REPORTED OUTCOMES
ARCHER 1042: A PHASE 2 STUDY OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (POST-CHEMOTHERAPY OR SELECT FIRST LINE PATIENTS) TO EVALUATE PROPHYLACTIC INTERVENTION ON DERMATOLOGIC AND GASTROINTESTINAL ADVERSE EVENTS AND PATIENT REPORTED OUTCOMES
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92037, United States
Los Angeles, California 90095, United States
Los Angeles, California 90095, United States
Los Angeles, California 90095, United States
Santa Monica, California 90404, United States
Fort Lauderdale, Florida 33308, United States
Chicago, Illinois 60612, United States
Chicago, Illinois 60637, United States
Brownstown, Michigan 48183, United States
West Bloomfield, Michigan 48322, United States
Springfield, Missouri 65807, United States
New York, New York 10032, United States
Burlington, Vermont 05405, United States